Overview

• The MTBR-tau243 blood test detects tau tangles associated with Alzheimer’s disease with 92% accuracy, distinguishing it from other dementias.
• This test correlates tau protein levels in the blood with the severity of cognitive decline, enabling disease staging and progression tracking.
• Researchers emphasize its potential to personalize treatment by identifying patients in early or advanced stages of Alzheimer’s, optimizing therapy effectiveness.
• The test could accelerate drug development by providing a faster, less invasive way to measure the impact of experimental treatments targeting tau tangles.
• While promising, the test requires further validation and development before it can be widely adopted for routine clinical use.